Insulin Susp Isophane Semisynthetic Purified Human
drugOn this page
Summary
Insulin Susp Isophane Semisynthetic Purified Human (CHEMBL1201627) is an approved protein; indicated across 6 conditions including hypertensive disorder and atherosclerosis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Indications: 6 conditions
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201627 |
| Name | Insulin Susp Isophane Semisynthetic Purified Human |
| Type | Protein |
| Max phase | 4 |
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hypertensive disorder | 3 | MONDO:0005044 | EFO:0000537 |
| atherosclerosis | 3 | MONDO:0005311 | EFO:0003914 |
| coronary artery disorder | 3 | MONDO:0005010 | EFO:0001645 |
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
| hyperglycemia | 2 | MONDO:0002909 | HP:0003074 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).